Read about how other health conditions you may have, called comorbidities, affect trial participation, as well as efforts to include more people with comorbidities in trials.
Learn how experts develop and refine MBC treatment guidelines using evidence from MBC clinical trials.
Read for information on the FDA’s expanded approval of Trodelvy® and ASCO’s updated guidance on the use of this drug.
Read about stable disease and current research on monitoring MBC treatment response.
In part 3 of a 3-part series, learn about biomarkers that require more research before being recommended to guide treatment decisions.
In part 2 of a 3-part series, read about the new recommendations and the dMMR/MSI-H, TMB, and NTRK fusion biomarkers.
In this part 1 of a 3-part series, read about new recommendations for using biomarkers to make MBC treatment decisions.
Last in our series, hear from researchers on the latest metastatic lobular breast cancer research.
Next in our series, hear from experts in cancer metastasis to the lungs (or lung mets).
Next in our series, hear from a panel of MBC liver metastasis experts.
